ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL

Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R- | Seeking a share of the first-line diffuse B-cell lymphoma market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-CHOP regimen and Roche’s Polivy—that’s at least before newer agents such as T-cell engagers catch up.

Raccontata dafiercepharma.comfiercebiotech.comendpoints.news